Category: Diabetes

Introduction and Objective: The Soli-SWITCH study assessed the efficacy and safety of switching to iGlarLixi, an injectable fixed-ratio combination therapy of insulin glargine 100 U/mL + lixisenatide, in people with T2DM uncontrolled on premix insulin in a clinical trial setting. The aim of the study is to assess the efficacy and safety of such transition […]

Introduction and Objective: Nearly half of US adults with type 2 diabetes (T2D) fail to achieve glycemic control (A1c<7%), increasing complication risks. The American Diabetes Association recommends system-level strategies to optimize care delivery, yet the real-world impact of population-based programs on A1c control remains unclear. This study examined the association between three key components of […]

Introduction and Objective: Accurate initial insulin dosing is essential for optimal glycemic control in type 2 diabetes patients with insulin pumps. Traditional weight-based estimations lack precision due to the heterogeneity of type 2 diabetes, underscoring the need for advanced predictive approaches. This study developed machine learning models to enhance the accuracy of initial premeal and […]

Introduction and Objective: Obesity, as measured by body mass index (BMI), is associated with sleep deficiency and disorders; however, body fat distribution is a more accurate measure. Our aim was to evaluate the association between regional body fat distribution and sleep patterns using questionnaires and 24-hour actigraphy.Methods: The Dallas Heart and Minds Study is a […]

Introduction and Objective: Fast-acting insulin analogs (FIA) have earlier and higher peak and shorter duration of action as compared with short-acting human insulin (SHI). Therefore, their pharmacokinetic profile would rather reflect glycemic profile after high-carbohydrate meal (HCM), whereas delayed and longer action of SHI would rather reflect glycemia after low-carbohydrate meal (LCM).Methods: In a cross-over, […]

Introduction and Objective: Diabetic retinopathy (DR) is associated with hyperglycemia and inflammatory biomarkers such as Vascular Endothelial Growth Factor. Another molecule, Endocrine Gland-derived Vascular Endothelial Growth Factor (EG-VEGF) is present in human sera and is hypothesized to play a role in angiogenesis. We aim to determine whether DR severity is correlated to circulating levels of […]

Introduction and Objective: This trial assessed the PD, PK, and safety of SHR-3167 vs IGlar U100 in healthy subjects.Methods: This was an open-label, two-period, single-sequence trial. Sixteen healthy males were enrolled into two cohorts. Both cohorts received a single injection of IGlar U100 (0.4 U/kg), following a 7-day washout, and then received a single injection […]

Introduction and Objective: Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) affects ~60% of those with T2DM yet is under-recognized, even in specialty endocrinology practices. This Quality Improvement study aims to assess baseline MASLD screening rates in a diabetes clinic and evaluate whether an EHR-based intervention increases disease recognition and early management.Methods: Medical charts from an […]

Introduction and Objective: QWINT-2 met its primary endpoint, with once weekly efsitora noninferior to once-daily degludec in reducing HbA1c at 52 weeks when added to existing noninsulin glucose-lowering agents in insulin-naïve adults with T2D. A Japan subgroup analysis is shown.Methods: QWINT-2 (NCT05362058) was a phase 3, randomized, parallel-design, open-label study. Participants were randomized 1:1 to […]

Introduction and Objective: To assess prevalence and factors for treatment failure with SGLT2i in US adults with T2D.Methods: This was a retrospective cohort study among US adults with T2D who initiated SGLT2i between January 1, 2016 and April 30, 2024, using the Komodo Healthcare MapTM database. Treatment failure occurred if they discontinued SGLT2i, added or […]